Navigation Links
QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President

New Hire Brokered Deals valued at more than $3.0 Billion

SYDNEY, Australia and BEDMINSTER, N.J., Jan. 22 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today that Jesus Soriano, MD, PhD, MBA will serve as Executive Vice President. Dr. Soriano brings more than 17 years of experience in healthcare management, basic and clinical research, professional services, regulatory compliance, licensing and business development, including negotiating and executing deals with present and future value of more than US$3.0 billion.

"We are very pleased to announce that Dr. Soriano has joined our senior management team," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Our approach has been to build a team of people who add value, broaden our collective knowledge and bring the experience necessary to advance the Company's goals. I am confident Dr. Soriano will contribute significantly to QRxPharma's success."

Prior to joining QRxPharma, Soriano was Senior Director of Business Development at Osiris Therapeutics, Inc., and responsible for all business development activities, including IP strategy and operations, out-licensing and divestiture. During Dr. Soriano's tenure, Maryland-based Osiris Therapeutics formed a $1.4 billion partnership with Genzyme Corp. for the development and commercialisation of Prochymal(TM) and Chondrogen(TM), two first-in-class, late-stage adult stem cell products. Dr. Soriano also played a critical role in the divestiture of Osteocel(R) to NuVasive, Inc., worth up to $137 million. Preceding Osiris, Dr. Soriano spent five years at American Type Culture Collection (ATCC) in a variety of leadership positions, including Vice President for IP, Licensing and International Business Development. At ATCC, Dr. Soriano managed all commercial operations related to intellectual property, licensing, services and international business development.

"I am pleased to join this exceptional team at a time when Phase 3 clinical trials are well advanced and we are preparing for the commercialisation of MoxDuo IR (TM) within the next two years," said Dr. Soriano. "QRxPharma is a dynamic specialty pharmaceutical company with a strong pipeline, a very innovative intellectual property and the potential for a tremendous global franchise in pain management and CNS drug development. I am excited to have the opportunity to work with the QRxPharma team to accelerate business development and extend the global reach of the Company."

The Company's Dual Opioid (TM) products target moderate to severe pain, a $7 billion US prescription market. The goal is to provide a greater therapeutic index (fewer dose-limiting side effects) and a more broad selection of analgesic options to pain specialists. QRxPharma is on track to launch its first dual opioid product, MoxDuo IR (TM) (Q8003IR), in 2011. QRxPharma remains open and committed to finding the best possible business relationships to expand the US and overseas markets, accelerate revenues, and maximise the value of its product portfolio while providing significant financial return to its shareholders. QRxPharma will initially focus operations in North America and seeks strategic partners for Europe, Australia and Asia.

Jon Merriman, CEO of Merriman Curhan Ford - the investment bank that serves as QRxPharma's Principal American Liaison on the International OTCQX - commented: "We believe Dr. Soriano is a very strong addition to QRxPharma's senior management team. Our OTCQX Advisory Group looks forward to introducing him to U.S. institutional investors interested in QRxPharma's story."

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third

parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX, OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo IR (TM) (Q8003IR), the first combination opioid product for the improved control of moderate to severe pain, successfully completed Phase 3 studies and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information:

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
2. QRxPharma Begins Trading on the International OTCQX
3. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
4. Rohm and Haas Expands in India
5. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
6. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
7. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
8. Specialty Blades, Inc. Expands Management Team With New VP Engineering
9. CRH Medical expands Las Vegas operations
10. US Med-Equip Expands Corporate Support Center
11. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
Post Your Comments:
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
(Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
Breaking Medicine Technology: